Compare RAYMED LABS. with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

RAYMED LABS vs ALEMBIC PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    RAYMED LABS ALEMBIC PHARMA RAYMED LABS/
ALEMBIC PHARMA
 
P/E (TTM) x -6.6 18.0 - View Chart
P/BV x - 2.8 - View Chart
Dividend Yield % 0.0 1.9 -  

Financials

 RAYMED LABS   ALEMBIC PHARMA
EQUITY SHARE DATA
    RAYMED LABS
Mar-21
ALEMBIC PHARMA
Mar-21
RAYMED LABS/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs11,150 0.1%   
Low Rs1527 0.2%   
Sales per share (Unadj.) Rs0274.4 0.0%  
Earnings per share (Unadj.) Rs-0.256.7 -0.3%  
Cash flow per share (Unadj.) Rs-0.166.0 -0.2%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Avg Dividend yield %01.7 0.0%  
Book value per share (Unadj.) Rs-4.8260.9 -1.8%  
Shares outstanding (eoy) m4.27196.56 2.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio xNM3.1-  
Avg P/E ratio x-5.914.8 -40.1%  
P/CF ratio (eoy) x-6.512.7 -50.8%  
Price / Book Value ratio x-0.23.2 -6.2%  
Dividend payout %024.7 0.0%   
Avg Mkt Cap Rs m4164,818 0.0%   
No. of employees `000NANA-   
Total wages/salary Rs m010,512 0.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m053,931 0.0%  
Other income Rs m0875 0.0%   
Total revenues Rs m054,806 0.0%   
Gross profit Rs m-114,801 -0.0%  
Depreciation Rs m01,835 0.0%   
Interest Rs m0160 0.0%   
Profit before tax Rs m-113,681 -0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m02,533 0.0%   
Profit after tax Rs m-111,148 -0.0%  
Gross profit margin %NM27.4- 
Effective tax rate %018.5 0.0%   
Net profit margin %NM20.7- 
BALANCE SHEET DATA
Current assets Rs m125,779 0.0%   
Current liabilities Rs m2312,808 0.2%   
Net working cap to sales %NM24.1- 
Current ratio x02.0 1.9%  
Inventory Days DaysNM23- 
Debtors Days DaysNM24- 
Net fixed assets Rs m241,311 0.0%   
Share capital Rs m43393 10.9%   
"Free" reserves Rs m-6350,883 -0.1%   
Net worth Rs m-2151,276 -0.0%   
Long term debt Rs m01,999 0.0%   
Total assets Rs m367,090 0.0%  
Interest coverage xNM86.4-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x00.8 0.0%   
Return on assets %-27.316.9 -162.0%  
Return on equity %3.421.7 15.4%  
Return on capital %3.426.0 12.9%  
Exports to sales %NM66.8-  
Imports to sales %NM12.7-  
Exports (fob) Rs mNA36,020 0.0%   
Imports (cif) Rs mNA6,845 0.0%   
Fx inflow Rs m036,020 0.0%   
Fx outflow Rs m06,845 0.0%   
Net fx Rs m029,175 0.0%   
CASH FLOW
From Operations Rs m014,634 0.0%  
From Investments Rs mNA-8,388 0.0%  
From Financial Activity Rs mNA-5,974 0.0%  
Net Cashflow Rs m0262 0.0%  

Share Holding

Indian Promoters % 28.4 69.0 41.1%  
Foreign collaborators % 0.0 0.5 -  
Indian inst/Mut Fund % 1.0 17.5 5.5%  
FIIs % 0.0 5.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 71.6 30.5 234.7%  
Shareholders   1,478 110,038 1.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare RAYMED LABS With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Sensex Corrects Over 1,000 Points as Fed Signals Rate Hike; Realty & IT Stocks Bleed(10:30 am)

Asian stock markets fell sharply today, tracking losses across Asia and Wall Street after Federal Reserve chief Jerome Powell confirmed the bank will lift interest rates in March.

Related Views on News

ALEMBIC PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Jul 8, 2021 | Updated on Jul 8, 2021

Here's an analysis of the annual report of ALEMBIC PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

Insiders are Buying into these 6 Stocks Aggressively. More Details here...(Views On News)

Jan 19, 2022

While promoter holding is an important parameter, it should not be the sole reason for buying a stock.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

RAYMED LABS SHARE PRICE


Jan 24, 2022 (Close)

TRACK RAYMED LABS

  • Track your investment in RAYMED LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

RAYMED LABS 5-YR ANALYSIS

COMPARE RAYMED LABS WITH

MARKET STATS